Startups
Damona Pharmaceuticals
Develops small-molecule medicines for cognitive impairment associated with Alzheimer’s disease, depression, schizophrenia and other brain disorders. Its lead investigational drug, DPX-101, selectively enhances α5-GABA-A receptor activity to support neuronal signaling and connections. The program has FDA clearance for Phase 1 clinical testing; cognitive benefits described so far come from preclinical studies.
Team
Etienne SibilleScientific Founder and Board Director |
Guy GriebelScientific Advisory Board Member |
Jacki JenuthBoard Director |
 James SummersBoard Director |
Jeff IrwinChief Financial Officer |
John KrystalScientific Advisory Board Member |
John ReillyChief Executive Officer and Board Director |
 Maurizio FavaScientific Advisory Board Member |
Richard KeefeScientific Advisory Board Member |
Rob RisingerConsulting Chief Medical Officer |
Sri Teja MullapudiBoard Director |
Thomas ThestrupBoard Director |